Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

WuXi PharmaTech and OMT Announce OmniRat™ Antibody Collaboration

Published: Thursday, January 17, 2013
Last Updated: Wednesday, January 16, 2013
Bookmark and Share
OmniRat™ technology allows WuXi to expand its service offerings in discovery of fully human antibodies.

WuXi PharmaTech and Open Monoclonal Technology, Inc. (OMT), have announced that they have entered into an agreement to use OMT’s OmniRat™ to develop therapeutic antibody candidates for commercialization by WuXi’s global customers.

This transaction advances WuXi’s goal of working with skilled partners to enhance the company’s platform of technologies and capabilities to serve its customers better.

The OmniRat™ technology generates fully human antibodies with great specificity, affinity and manufacturability. It eliminates time-consuming humanization of traditional mouse-derived antibodies and the need for optimization of lead candidates using phage display technology.

“OMT’s OmniRat™ technology allows WuXi to expand its service offerings in discovery of fully human antibodies,” said Edward Hu, Chief Operating Officer and Chief Financial Officer of WuXi PharmaTech.

Hu continued, “Providing discovery, development and manufacturing services for novel therapeutic antibodies represents an important new global business initiative for WuXi. We are investing heavily in building our capabilities and capacity in biologics services, which we expect to be a key driver of revenue growth for our company in the coming years.”

Dr. Roland Buelow, founder and CEO of OMT, continued, “The collaboration with WuXi further advances OMT’s efforts to deploy its human antibody platform globally. Under the collaboration, OMT can leverage WuXi’s expertise and capacity to create novel therapeutic candidates for its biopharmaceutical customers and apply OMT’s technology to an ever-broadening base of drug candidates.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trellis and OMT Announce Therapeutic Antibody Discovery Collaboration
Companies will join forces to generate human antibodies against therapeutic targets using OMT’s OmniRat™ platform.
Tuesday, October 09, 2012
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!